BiBBInstruments (BIBB) Q2 2026 earnings summary

Executive summary

• Achieved first European distribution agreement with Palex Medical Spain and received initial order for EndoDrill® GI, marking commercial expansion in Europe.

• Continued US market introduction with TaeWoong Medical USA, achieving highest quarterly sales since launch.

• Strengthened clinical evidence with positive results from leading US hospitals and expanded global patent portfolio.

Financial highlights

• Q2 2026 net sales reached 472 KSEK, up from 0 KSEK in Q2 2025; H1 2026 net sales were 585 KSEK, up from 39 KSEK year-over-year.

• Q2 2026 operating loss was -5,635 KSEK (vs. -3,890 KSEK in Q2 2025); H1 2026 operating loss was -10,430 KSEK (vs. -6,752 KSEK in H1 2025).

• Cash and cash equivalents at June 30, 2026, were 35,443 KSEK, up from 15,814 KSEK a year earlier.

• Equity increased to 64,825 KSEK from 45,550 KSEK year-over-year.

Outlook and guidance

• Financial resources from the rights issue are expected to fund operations through 2026 and 2027.

• Focus remains on US market development, European expansion, and EndoDrill® platform advancement.